On the other hand, circulating Th17 cells were reported to increase at 6 months post TNF inhibitor therapy in inadequate responders12 and in the blood of previously biologic-naive RA subjects showing a good response to Etanercept or Adalimumab therapy39. The gene discussed is TNF; the disease is rheumatoid arthritis.